Breaking News, Collaborations & Alliances

Porton, Aojin Partner to Advance XDC Conjugate Drugs for Dual IND Filings in China & the U.S.

Aim to promote the vigorous development of global XDC conjugate drugs, enabling the public's early access to good medicines.

Author Image

By: Charlie Sternberg

Associate Editor

Porton Pharma Solutions Ltd., an end-to-end CDMO, has teamed up with Aojin Life Sciences (Yixing) Co., Ltd. to offer extensive CDMO services for Aojin in the CMC pharmaceutical research and GMP production of XDC conjugate drugs, focusing on dual IND filings in both China and the United States.   With nearly two decades of experience in providing integrated CDMO services, Porton has formed a multidisciplinary project team that connects drug substance and drug product technologies, blending expe...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters